Renal Denervation for Uncontrolled Hypertension
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This draft policy governs coverage of radiofrequency and ultrasound renal denervation as a treatment for uncontrolled hypertension for BCBSRI Commercial Products; Medicare Advantage follows CMS NCD/LCD guidance. It applies to providers seeking coverage decisions for eligible commercial members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Renal Denervation
Medical necessity — RFA or Ultrasound Renal Denervation
Covered when ALL of the following are met:
General coverage stance
When the medical criteria in the policy are met, the following are considered medically necessary:
Providers should verify member-specific benefits and obtain any required authorizations per subscriber or employer agreements.
The following indications are explicitly listed as not medically necessary because the evidence is insufficient to show improvement in net health outcome: stage 1 hypertension; isolated systolic hypertension; stage 4 or 5 chronic kidney disease; single kidney; kidney transplant recipients; and redo renal denervation in individuals who fail to respond to initial renal denervation.
This medical policy is provided for informational purposes and is not a guarantee of payment. Benefits and eligibility for services are determined by the member's subscriber agreement, member certificate, and/or employer agreement, which supersede this policy. Providers should verify member-specific benefits with the payer prior to delivering services.
When the policy's medical criteria are not met, radiofrequency or ultrasound renal denervation is considered not medically necessary because current evidence is insufficient to determine that the procedure improves net health outcome.
If services are determined to be not medically necessary or are non-covered benefits according to the member's documents, the provider may not charge the member for those services unless the member has been informed and has provided prior written agreement to accept financial responsibility.
Coding
| 0338T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral |
| 0339T | Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral |
Provider Actions and Requirements
Prior authorization — Not applicable
Prior authorization is not required for renal denervation under this policy.
Verify benefits and obtain authorization as required
Verify member-specific benefits and obtain prior authorization when required by the member's subscriber or employer agreement; this policy is informational and not a guarantee of payment.
- Contact the provider call center or review the member's subscriber agreement to confirm coverage and any authorization requirements.
Medication therapy requirement — ≥3 antihypertensive classes
Patient eligibility expects attempted medical therapy with at least three antihypertensive medication classes and persistent uncontrolled blood pressure despite those agents, or documented intolerance.
- Required medication classes enumerated include ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, and beta blockers.
Prior medical therapy context — use after failed medications
Clinical evidence and policy context apply to patients with uncontrolled hypertension despite antihypertensive medications; trials compared renal denervation to sham and medical therapy, supporting use after prior medical management.
Required clinical documentation
Documentation must show uncontrolled blood pressure despite lifestyle modifications and use of three or more antihypertensive medications from different classes at maximally tolerated doses or documented intolerance, plus evidence of shared decision-making and treatment at an experienced multidisciplinary hypertension center.
- Include medication names, classes, doses, duration, and reason for intolerance if applicable.
- Document blood pressure measurements and evidence of lifestyle modification attempts and shared decision-making.
Coding and benefits verification — CPT & HCPCS apply
When the medical criteria are met use CPT codes 0338T (unilateral) or 0339T (bilateral) and HCPCS codes C1735 (radiofrequency catheter) or C1736 (ultrasound catheter); verify member benefits and obtain any required authorizations per subscriber/employer agreements.
Denial triggers — excluded indications
Procedures performed for excluded indications (stage 1 hypertension; isolated systolic hypertension; stage 4 or 5 chronic kidney disease; single kidney; kidney transplant recipients; or redo renal denervation) are considered not medically necessary and may be denied.
- Confirm indication against policy exclusions before scheduling to avoid denials.
Member financial liability and denial risk
If services are determined not medically necessary or are non-covered per the member's benefit documents, the provider may be unable to charge the member unless a prior written agreement is obtained.
- Obtain written member agreement in advance if proceeding with non-covered services if permitted by participation agreements.
Background
Renal denervation (performed with radiofrequency or intravascular ultrasound energy) is intended to reduce sympathetic renal nerve signaling by ablating renal sympathetic nerves via a percutaneous transcatheter approach. The procedure aims to lower blood pressure by interrupting renal sympathetic output to the kidney.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.